Table 2.
FDA-approved PD-1 inhibitors which have displayed significant PD-1 inhibition in preclinical trials.
| Emerging PD-1 Inhibitors | Features | Cancer Type | Reference |
|---|---|---|---|
| Cemiplimab | Fully human hinge stabilized IgG4 anti-PD-1 antibody | CSCC patients (both metastatic or locally advanced) |
[32] |
| Sintilimab | PD-1 targeted human IgG4 mAb (monoclonal antibody) | Gastric carcinoma (NCT03745170) | [33] |
| Lymphoma (NCT04052659) | |||
| Oesophageal carcinoma (NCT03946969) | |||
| NSCLC (NCT03830411) | |||
| Nasopharyngeal cancer (NCT03700476) | |||
| Tislelizumab | PD-1 targeted humanized IgG4 mAb | Hodgkin’s lymphoma (both relapsed and refractory) | [34] |
| Nasopharyngeal carcinoma (NCT03924986) |
[35] | ||
| UC (NCT03967977) | |||
| Gastroesophageal or gastric junction cancer (NCT03777657) | |||
| Lymphoma (NCT03493451) | |||
| Oesophageal carcinoma (NCT03957590) | |||
| NSCLC (NCT03358875) | |||
| Toripalimab | Humanized IgG4 anti PD-1 mAb | Metastatic melanoma patients who did not respond to systemic therapies | [36] |
| Liver cancer (NCT03949231) | [37] | ||
| Oesophageal cancer (NCT03829969) | |||
| Neck and head cancer (NCT03952065), | |||
| Melanoma (NCT03941795), | |||
| NSCLC (NCT03924050), | |||
| Neuroendocrine carcinoma of the bladder (NCT03992911) | |||
| Nasopharyngeal carcinoma (NCT03581786) | |||
| Spartaliumab | IgG4 PD-1 targeted mAb | Phase III COMBI-I trial (NCT02967692) in BRAFV600 mutant metastatic or unresectable melanoma | [38] |
| triple-negative breast cancer treatment (TNBC; NCT03499899) | |||
| RCC (NCT04028245) | |||
| NSCLC (NCT03647488) | |||
| Nasopharyngeal carcinoma and colorectal cancer (NCT03891953) |